Neoplasma Vol.69, No.5, p.1108–1118, 2022
|
Title: SPAG1 promotes the development of AML by activating the ERK/MAPK signaling pathway and affects the chemotherapy sensitivity of venetoclax |
Author: Lu Liu, Jing Liu, Xiao-Jun Liu, Meng-Han Liu, Xue-Feng Feng, Lin Yang, Jian-Min Luo |
|
Abstract: Sperm-associated antigen 1 (SPAG1) is considered to be associated with infertility and tumorigenesis. However, its function in acute myeloid leukemia (AML) remains unclear. In this study, we evaluated the expression level of SPAG1 and explored its clinical prognostic value in patients with AML, as well as its biological function in AML cells. SPAG1 is widely expressed in AML patients, resulting in a poor prognosis. However, its expression was not associated with Fms-related receptor tyrosine kinase 3 (FLT3) mutations. Utilizing the RNA interference knockdown tests, we found that SPAG1 could promote the proliferation and survival of AML cells and regulate the expression of structural maintenance of chromosomes protein 3 (SMC3), activating the ERK/MAPK signaling pathway. Furthermore, we discovered that inhibiting SPAG1 impacted AML cell susceptibility to venetoclax. In conclusion, SPAG1 may serve as a potential therapeutic target in AML.
|
|
Keywords: acute myeloid leukemia; sperm associated antigen 1; MAPK; venetoclax; biomarker |
|
Published online: 11-Aug-2022
|
Year: 2022, Volume: 69, Issue: 5 |
Page From: 1108, Page To: 1118 |
doi:10.4149/neo_2022_220415N416
|
|
download file |
|
|
|
|